Recent years have witnessed transformative technological leaps in molecular diagnostics, notably the rapid expansion of next-generation sequencing (NGS) multiplex panels, high-throughput digital PCR systems, and CRISPR-based nucleic acid detection tools. Additionally, the emergence of liquid biopsy technology—which isolates circulating tumor DNA and cellular RNA from routine blood draws—has revolutionized non-invasive cancer screening, early detection, and real-time monitoring of minimal residual disease.